Does EVEROLIMUS Cause Second primary malignancy? 218 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 218 reports of Second primary malignancy have been filed in association with EVEROLIMUS (EVEROLIMUS). This represents 0.6% of all adverse event reports for EVEROLIMUS.
218
Reports of Second primary malignancy with EVEROLIMUS
0.6%
of all EVEROLIMUS reports
48
Deaths
81
Hospitalizations
How Dangerous Is Second primary malignancy From EVEROLIMUS?
Of the 218 reports, 48 (22.0%) resulted in death, 81 (37.2%) required hospitalization, and 5 (2.3%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVEROLIMUS. However, 218 reports have been filed with the FAERS database.
What Other Side Effects Does EVEROLIMUS Cause?
Death (5,090)
Malignant neoplasm progression (3,789)
Diarrhoea (3,061)
Fatigue (2,946)
Stomatitis (2,692)
Nausea (2,079)
Dyspnoea (1,925)
Drug ineffective (1,837)
Pyrexia (1,664)
Decreased appetite (1,633)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which EVEROLIMUS Alternatives Have Lower Second primary malignancy Risk?
EVEROLIMUS vs EVOLOCUMAB
EVEROLIMUS vs EXELON
EVEROLIMUS vs EXEMESTANE
EVEROLIMUS vs EXENATIDE
EVEROLIMUS vs EXFORGE